 |
인쇄하기
취소
|
Yungjin Pharm to market HEXAL’s Amlocard tablet
Yungjin Pharm said on October 4 it has obtained exclusive marketing and distribution rights to HEXAL’s Amlocard (amlodipine besylate) tablet for the treatment of hypertension in Korea.
Amlocard tablet, which was approved in 15 European countries including Germany, Denmark and Austria, has been recognized as an antihypertensive agent with more than two-year stability data.
HEXAL AG, locate...
Amlocard tablet, which was approved in 15 European countries including Germany, Denmark and Austria, has been recognized as an antihypertensive agent with more than two-year stability data.
HEXAL AG, locate...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.